The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer
暂无分享,去创建一个
[1] J Dequeker,et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. , 1995, The New England journal of medicine.
[2] P. Kelly,et al. Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women. , 1993, Bone and mineral.
[3] L. Davis. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. , 1998, Journal of nurse-midwifery.
[4] S. Cummings,et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.
[5] P. Rissanen,et al. Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase II study. , 1988, European journal of cancer & clinical oncology.
[6] H. Genant,et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. , 1990, The New England journal of medicine.
[7] P. Hietanen,et al. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. , 1998, The Journal of clinical endocrinology and metabolism.
[8] Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. , 1990, The New England journal of medicine.
[9] I. Reid,et al. The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. , 1995, The American journal of medicine.
[10] T. Powles,et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] R B Mazess,et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. , 1992, The New England journal of medicine.
[12] R. Lindsay,et al. BONE RESPONSE TO TERMINATION OF ŒSTROGEN TREATMENT , 1978, The Lancet.
[13] C. Christiansen,et al. BONE MASS IN POSTMENOPAUSAL WOMEN AFTER WITHDRAWAL OF OESTROGEN/GESTAGEN REPLACEMENT THERAPY , 1981, The Lancet.
[14] C. Blomqvist,et al. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] A. LaCroix,et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.
[16] H. Fleisch. Bisphosphonates in Bone Disease: From the Laboratory to the Patient , 2000 .
[17] R. Recker,et al. Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis , 1996 .
[18] R. Lindsay,et al. BONE RESPONSE TO TERMINATION OF OESTROGEN TREATMENT , 1978 .
[19] Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. , 1994, The American journal of medicine.
[20] J. Pouilles,et al. Effect of menopause on femoral and vertebral bone loss , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[21] H. Mouridsen,et al. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] C. Blomqvist,et al. Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens. , 1997, British Journal of Cancer.